Business Context and Reporting Period
Company: Albemarle Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1998
Business Overview: Albemarle operates in the specialty chemicals sector, producing products such as pharmachemicals, flame retardants, polymer additives, organometallics, and agrichemicals. The company is subject to environmental regulations and engages in new product development and strategic acquisitions.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Net Sales | $215.1 million | $198.4 million |
| Gross Profit | $67.8 million | $66.4 million |
| Operating Profit | $34.2 million | $32.4 million |
| Net Income | $22.6 million | $20.2 million |
| Diluted EPS | $0.42 | $0.36 |
| Cash from Operations | $52.8 million | $15.5 million |
| Cash and Equivalents (End of Period) | $42.2 million | $2.6 million |
| Long-Term Debt (Total) | $89.3 million | $91.8 million |
Margins: Gross margin was approximately 31.5% in Q1 1998. Management noted that excluding foreign exchange gains, the gross margin would have been 31.1% in both periods. Selling, general, and administrative (SG&A) plus R&D expenses were 15.6% of net sales in 1998, down from 17.1% in 1997.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% ($16.8 million) driven by higher shipments of pharmachemicals, flame retardants, and polymer additives, partially offset by lower prices in polymer additives.
- Cost Structure: Cost of goods sold rose 12% due to higher shipment volumes and reduced foreign exchange gains compared to 1997. Operating expenses declined slightly due to cost reduction programs and lower consulting costs.
- Profitability: Operating profit increased 6%. Net income rose 12% to $22.6 million, aided by a lower effective tax rate (33.2% in 1998 vs. 37.4% in 1997).
- Liquidity: Cash and cash equivalents increased by $7.9 million to $42.2 million. Operating cash flow improved significantly to $52.8 million from $15.5 million in the prior year.
- Debt: Total long-term debt decreased slightly to $89.3 million. Interest expenses increased to $1.0 million from $0.2 million due to higher average outstanding debt.
Outlook, Risks, and Management Commentary
- Currency Impact: The strengthening U.S. dollar against the Japanese yen and Deutsche mark negatively impacted results. Management expects this trend to continue through 1998 and is utilizing forward exchange contracts to mitigate effects.
- Capital Expenditures: Q1 1998 capital spending was lower than Q1 1997, but full-year 1998 spending is forecasted to exceed 1997 levels, financed primarily by operating cash flow.
- New Products: Two new flame retardants are in customer qualification. Ethacure 300 curative is scheduled for plant start-up in mid-1998. Naproxen sales continue to lag expectations.
- Market Conditions: Strong demand persists for polymer chemicals in the Asia Pacific region despite local economic conditions. No significant volume reductions have been observed.
- Risks: The company faces potential liabilities from environmental laws (e.g., Superfund) and product liability litigation, though management does not expect these to have a material adverse effect. Future results depend on order timing, competition, and raw material costs.
Investor Verification Checklist
- Verify the sustainability of the 8% sales growth given the offsetting impact of lower prices in polymer additives.
- Monitor the impact of the strengthening U.S. dollar on future margins and the effectiveness of hedging strategies.
- Track the commercial launch and sales performance of new products, specifically Ethacure 300 and the new flame retardants.
- Assess the trajectory of Naproxen sales to determine if they will meet revised expectations.
- Review the full-year capital expenditure plan to ensure alignment with cash flow projections.